For & Against
What's Next
The next 3 to 6 months are dominated by one overlapping question: does the activist clock (JANA plus Browning West) force portfolio action before management's own capital-return contract (three-year $2.2B FCF, $2B buyback) earns the re-rate on its own. Two earnings prints, the first Rosebrough-era board meetings, and the December 2026 term-loan maturity are the observable markers.
Latest reported (Q1 FY26): EPS $1.10 vs consensus $1.03 (+6.8% surprise). COO has beaten in each of the last nine quarters, so the bar is less about the print and more about the guide. The specific things the market will watch most closely:
- CooperVision organic growth rate — bull's disconfirming signal is two consecutive quarters below 3%; bear's confirming signal is a second walk-down of the 4.5-5.5% FY26 guide.
- Fertility print — CooperSurgical fertility was 1% in Q4 FY25 and 3% in Q1 FY26; whether it returns toward high-single digits will decide if the "Trump IVF overhang" reading was real or a structural reset.
- Any board statement on strategic review — JANA's CVI-to-Bausch+Lomb proposal and Browning West's CSI-sale alternative both need a board response; silence through Q3 FY26 tips the clock toward 2027 proxy pressure.
- Tariff / gross-margin commentary — Q1 FY26 disclosed tariffs kept gross margin flat; any escalation hits 65.5% GM directly.
For / Against / My View
For
Bull's price target: $103 per share, 12-18 months — anchored on model Fair Value of $103 (Numbers tab), which implies ~18x EV/EBITDA (the 20-year mean) on ~$1.1B EBITDA. No multiple expansion beyond reversion to long-run average, no growth heroics. Bull-case upside to $115-$150 if a JANA-driven breakup or CVI-only multiple recognition occurs.
First sub-20-year-mean EV/EBITDA since 2010
COO trades at 15.4x EV/EBITDA, roughly 0.4 standard deviations below the 20-year mean of 17.9x and a full 5 turns below the 5-year mean of 20.5x — the first time the stock has been below its long-run average since 2008-2010. Model Fair Value is $103 versus a $64.96 close, a 58% gap, with Quality Score at 90/100 and Altman Z at 3.44 (safe).
Evidence: Numbers — "EV/EBITDA at 15.4x — roughly 0.4 standard deviations below the 20-year mean of 17.9x and a full 5 turns below the 5-year mean of 20.5x. That is the first time EV/EBITDA has traded under the 20-year average since the 2008-10 GFC window"; Fair Value $103 vs price $64.96 = 58% gap; Quality Score 90/100; Altman Z 3.44.
Every NEO bought stock with personal cash; zero sold
Ten open-market insider purchases in 2025, zero sales. CEO Albert White put in $1.49M of personal cash across two tranches (10,000 shares at $68.39 in September, another 10,000 at $80.80 in December). The CFO, COO/GC, President of CooperVision, and President of CooperSurgical all bought. Four independent directors joined. CEO "Compensation Actually Paid" collapsed 96% from $39.8M to $1.77M as TSR lagged — the pay plan is penalizing management, and they are still buying.
Evidence: People — "Ten open-market purchases, zero sales in 2025. Every single NEO (White, Andrews, McBride, Sheffield, Warner) bought stock with personal cash… CEO White put in $1.49 million across two transactions"; CEO CAP fell from $39.8M (FY24) to $1.77M (FY25) — a 96% drop as TSR moved from 100 to 67.
Activist catalyst is already live and structurally mispriced
JANA Partners is publicly pushing to break up CooperVision and CooperSurgical; Browning West has already placed director Walter Rosebrough (ex-STERIS CEO, 18% annualized TSR over 14 years) through a December 2025 cooperation agreement. Sum-of-parts math is compelling: CVI alone on Alcon's 18-22x EV/EBITDA multiple plus CSI on 11-14x against a blended 14x today implies a re-rating without any operational heroics. The board has already refreshed itself reactively — the next escalation is a strategic review or asset sale.
Evidence: People — "activist investor Jana Partners is pushing to break up CooperVision and CooperSurgical, and Browning West has already placed a director (Walter Rosebrough) through a December 2025 cooperation agreement"; Business — "Do a sum-of-parts: put CVI on 18-22x EV/EBITDA (its peers Alcon and J&J Vision Care trade there), put CSI on 11-14x"; Numbers bull case — "$115-$150 — Jana-driven breakup or re-rating to 22x EV/EBITDA."
Against
Bear's downside target: $54 per share, 12-18 months — methodology: apply 12x EV/EBITDA (midway between GFC-era trough of 8x and current 15.4x) to flat FY26 EBITDA of ~$1.04B = EV $12.5B, less ~$2.4B net debt = equity ~$10.1B on 198M diluted shares. Primary trigger: a second consecutive year of initial revenue guide being walked down by Q2 or Q3 FY26.
The growth algorithm already reset — and management still will not say so
FY25 initial organic revenue guide was 6 to 8 percent; actual was 4 percent, after three sequential walk-downs (6 to 8, then 5 to 6, then 4 to 4.5). CooperSurgical fertility — branded with "ten consecutive double-digit quarters" through FY23 — printed 1 percent in Q4 FY25 and 3 percent in Q1 FY26, and the streak was never acknowledged on a call. The FY26 initial guide of 4.5 to 5.5 percent organic implicitly confirms the new run rate, yet the stock still carries a FY25 P/E of 37 and a 5-year average EV/EBITDA of 20.5x — multiples earned when the business was compounding at double digits. A mid-single-digit medtech does not get 37x earnings once the buyside has watched the miss-and-reset pattern run twice.
Evidence: Story — "FY2025 guidance was initiated at 6-8%… walked down to 5-6%… then to 4-4.5%. Actual FY25 organic growth was 4%" and "Fertility grew 1% in Q4 FY25 and 3% in Q1 FY26 — the streak broke and management never acknowledged it." Numbers — 1Q25 yoy 3.6%, 4Q25 yoy 4.6% per quarterly_rev_yoy; current P/E 37.4 vs 20y mean 34.2 (val_anchors).
Sub-WACC ROIC exposes a decade of roll-up destruction
Reported ROIC of 3.8 percent is less than a quarter of Hologic's 15 percent or Edwards' 20 percent — because Cooper has put roughly $4.3 billion of acquisitions onto the books since FY16 (Cook Medical $1.6B in FY22; Generate Life $1.6B; obp Surgical $343M in FY24), carrying about $3.8B of goodwill. GAAP EPS is flat from FY19 to FY25; net income of $375M in FY25 is below $467M in FY19 despite revenue growing 54 percent over that span; and CooperSurgical operating margin collapsed from 9 to 3 percent on the Cook and obp integrations. The capital-return "pivot" is a tacit admission the deal pipeline does not clear the hurdle rate.
Evidence: Numbers — "ROIC has compressed to about 3.8%"; "about $4.3B of acquisitions since FY2016"; "CSI's operating margin collapsed from 9% to 3% in FY25" (Business). GAAP net income: 2019 $467M vs 2025 $375M (revenue_earnings_20y). People — Jana's October 2025 campaign on "$3B into CooperSurgical since 2017, returns on capital have declined, and the CEO was the former head of CooperSurgical."
The tape is methodical distribution, not a panic bottom
COO closed at $64.96 on April 23, 2026 — down 44 percent from the 2024 high of $115.90, 11th percentile of 52-week range, below the declining 200-day, RSI 26 with no bullish divergence, MACD back below zero after a failed lift. The last three earnings prints each produced a volatility spike (30-day realized vol hit 48 to 53 percent in April, June and September 2025) — serial repricing on each fundamental data point, not a single-shock drawdown. Relative strength has lagged SPY by 104 points and XLV by 42 points over three years and the gap is widening. Insider buying at $65 to $84 (September and December 2025) is already underwater.
Evidence: Technicals — "down roughly 44% from its 2024 all-time high," "11 points out of 100 on its own 52-week range," "RSI at 26," "Lagged SPY by 104 points and XLV by 42 points over 3 years," "Lose $61.78… the next visible support is the 2022 low near $63." People — CEO bought 10,000 shares at $68.39 on Sept 5 and 10,000 at $80.80 on Dec 16 — both above current $64.96.
The Tensions
1. Is 15.4x EV/EBITDA cheap, or correctly re-rated?
Bull says 15.4x is the first sub-20-year-mean print since the GFC and implies reversion to $103 with no growth heroics. Bear says the same 15.4x is still a premium for what is now a mid-single-digit grower with sub-WACC ROIC and a broken guide, and points out that the 20.5x five-year average was earned when organic was double-digit. Both cite the same data point: COO at 15.4x EV/EBITDA versus a 20-year mean of 17.9x and 5-year mean of 20.5x. This resolves on the FY26 initial guide credibility test at Q2 FY26 (late May 2026) and Q3 FY26 (August 2026) — two clean prints at 4.5 to 5.5 percent without a walk-down keeps the reversion case alive; one more walk-down confirms the bear's re-rating read.
2. Insider buying: conviction signal or anchor bias?
Bull says ten open-market buys with zero sales and $1.49M of CEO personal cash across two tranches is the cleanest alignment signal on a mid-cap. Bear says those exact same buys — 10,000 shares at $68.39 in September, 10,000 at $80.80 in December — are already underwater at $64.96, so the "most aggressive bull signal in the people tab is itself in the red." Both cite the same two CEO purchases at $68.39 and $80.80. This resolves on the next Form 4 window after Q2 FY26 earnings — a third open-market buy below $65 materially strengthens the conviction read; silence or a 10b5-1 sale schedule hardens the anchor-bias read.
3. The activist: catalyst or overhang?
Bull says JANA plus Browning West is the mechanism that crystallizes the sum-of-parts — CVI on 18-22x, CSI on 11-14x, blended 14x today. Bear says the activist campaign is precisely what a sub-WACC-ROIC conglomerate looks like when the market has stopped believing management, and absent an actual transaction it is an overhang that caps the multiple. Both cite the same JANA 13F position (3.5M shares, $289M, JANA's 2nd-largest holding) and the December 2025 Browning West cooperation agreement. This resolves on the Rosebrough Board Chair decision window (end of 2026) and any public board statement on strategic review — a formal review announcement or asset sale is the bull's proof; a 2027-proxy deferral with no transaction is the bear's proof.
My View
Close call, slight edge to the Against side for the next two quarters, and the reason is tension #1. The bull's "15.4x is cheap" argument and the bear's "15.4x is still a premium" argument sit on top of the same number, and the tie-breaker is whether the FY26 guide holds. Cooper has already walked down an initial guide three times in a single fiscal year; until we have seen Q2 FY26 and Q3 FY26 print inside the 4.5 to 5.5 percent band without a trim, the $2B buyback and the Fair Value anchor are catching a knife, not buying a trough. I would wait for the May earnings print before adding — the activist catalyst is real but it rhymes more with "overhang that eventually resolves" than with "imminent announcement," and Rosebrough's chair window is end of 2026, not next week. What would flip the view: one clean Q2 FY26 print with the 4.5 to 5.5 percent organic guide reiterated and CooperVision back above 5 percent — that turns the bull's mean-reversion math from hypothetical into probable, and the insider cash stops looking like an anchor.